Deutetrabenazine ( DrugBank: Deutetrabenazine )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	3

8. Huntington disease

---

Clinical trials : 229 /  Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04713982 (ClinicalTrials.gov)	November 19, 2021	6/1/2021	Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease	Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease	Huntington Disease	Drug: Deutetrabenazine	Vanderbilt University Medical Center	Teva Branded Pharmaceutical Products R&D, Inc.	Recruiting	18 Years	N/A	All	30	Phase 2/Phase 3	United States
2	NCT04301726 (ClinicalTrials.gov)	September 1, 2020	13/2/2020	Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD	Efficacy of Deutetrabenazine in Huntington's Disease Patients With Dysphagia: A Randomised, Placebo-controlled Pilot Study	Huntington Disease	Drug: Deutetrabenazine Oral Tablet [Austedo];Drug: Placebo oral tablet	Fundacion Huntington Puerto Rico	NULL	Not yet recruiting	21 Years	N/A	All	48	Phase 1	NULL
3	NCT04071639 (ClinicalTrials.gov)	March 12, 2020	26/8/2019	Symptomatic Therapy for Patients With Huntington's Disease	Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients	Huntington Disease	Drug: Haloperidol 2Mg Tab;Drug: Risperidone 1Mg Tab;Drug: Zoloft 50Mg Tablet;Drug: Idebenone;Drug: Deutetrabenazine Oral Tablet [Austedo]	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	N/A	N/A	All	60	Phase 1	China